ALKS

Over the past six months, Alkermes successfully acquired Avadel Pharmaceuticals in February 2026, strengthening its financial profile and entering the commercial sleep medicine market with LUMRYZ. The company reported strong Q1 2026 financial results in May, with significant revenues and the initiation of the Phase 3 Brilliance clinical program for alixorexton. Positive data for alixorexton in narcolepsy was announced in July 2025 and July 2026, with data published in The Lancet Neurology in August 2026 and detailed results from the Vibrance-2 study presented in June 2026. Alkermes reported strong Q2 2026 financial results in July, with significant proprietary product revenues. Blair Jackson assumed the role of CEO on August 1, 2026. Positive Phase 1b data for ALKS 7290 in ADHD was announced in September 2026, demonstrating clinical proof-of-concept and leading to a rebound in shares. ALKS stock has shown a 33.31% increase over the last year, trading around $40-$42 in early October 2026, despite sector-wide selling and macro concerns, with analysts having a median 12-month price target of $58.